Foresite Capital Opportunity Management V is an investment fund managing more than $39.7 million ran by James Tananbaum. There are currently 9 companies in Mr. Tananbaum’s portfolio. The largest investments include Pardes Biosciences Inc and Theseus Pharmaceuticals, Inc., together worth $21.4 million.
As of 5th August 2022, Foresite Capital Opportunity Management V’s top holding is 5,227,307 shares of Pardes Biosciences Inc currently worth over $16 million and making up 40.4% of the portfolio value.
In addition, the fund holds 959,275 shares of Theseus Pharmaceuticals, Inc. worth $5.31 million.
The third-largest holding is Compass Therapeutics, Inc. worth $4.12 million and the next is Gemini Therapeutics, Inc. worth $4.12 million, with 2,435,125 shares owned.
Currently, Foresite Capital Opportunity Management V's portfolio is worth at least $39.7 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Foresite Capital Opportunity Management V office and employees reside in Larkspur, California. According to the last 13-F report filed with the SEC, James Tananbaum serves as the Managing Member at Foresite Capital Opportunity Management V.
In the most recent 13F filing, Foresite Capital Opportunity Management V revealed that it had opened a new position in
Hims & Hers Health and bought 306,431 shares worth $1.39 million.
This means they effectively own approximately 0.1% of the company.
Hims & Hers Health makes up
100.0%
of the fund's Consumer Staples sector allocation and has decreased its share price by approximately 0.1% in the past year.
The investment fund also strengthened its position in Theseus Pharmaceuticals, Inc. by buying
490,455 additional shares.
This makes their stake in Theseus Pharmaceuticals, Inc. total 959,275 shares worth $5.31 million.
On the other hand, there are companies that Foresite Capital Opportunity Management V is getting rid of from its portfolio.
Foresite Capital Opportunity Management V closed its position in Cue Health Inc. on 12th August 2022.
It sold the previously owned 641,483 shares for $4.14 million.
James Tananbaum also disclosed a decreased stake in Quantum-si Incorporated by 0.6%.
This leaves the value of the investment at $1.47 million and 633,626 shares.
The two most similar investment funds to Foresite Capital Opportunity Management V are Power Corp Of Canada and Upfront Ventures Management. They manage $39.7 million and $39.7 million respectively.
Foresite Capital Opportunity Management V’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 12.0% of
the total portfolio value.
The fund focuses on investments in the United States as
33.3% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.13 billion.
These positions were updated on August 12th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Pardes Biosciences Inc |
No change
5,227,307
|
$16,048,000 | 40.44% |
| Theseus Pharmaceuticals, Inc. |
104.61%
959,275
|
$5,305,000 | 13.37% |
| Cue Health Inc. |
Closed
641,483
|
$4,138,000 | |
| Compass Therapeutics, Inc. |
41.30%
1,554,250
|
$4,119,000 | 10.38% |
| Gemini Therapeutics, Inc. |
No change
2,435,125
|
$4,115,000 | 10.37% |
| Kinnate Biopharma Inc. |
No change
291,667
|
$3,678,000 | 9.27% |
| Cullinan Oncology, LLC |
Closed
330,836
|
$3,464,000 | |
| Adicet Bio, Inc. |
No change
170,000
|
$2,482,000 | 6.26% |
| Quantum-si Incorporated |
60.35%
633,626
|
$1,470,000 | 3.70% |
| Hims & Hers Health, Inc. |
Opened
306,431
|
$1,388,000 | 3.50% |
| Enanta Pharmaceuticals Inc |
No change
22,750
|
$1,075,000 | 2.71% |
| No transactions found | |||
| Showing first 500 out of 11 holdings | |||